A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function
Completed · Not applicable
Conditions studied: Mild-to-Moderate COVID-19
In brief
This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.
Key facts
- Study ID
- NCT04486482
- Run by
- Kaleido Biosciences
- People needed
- 49
- Starts
- 2021-01-12
- Expected to finish
- 2021-03-30
- Last updated by the study team
- 2021-08-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cullman Clinical Trials — Cullman, Alabama, United States
- American Institute of Research — Los Angeles, California, United States
- Rancho Cucamonga Clinical Research — Rancho Cucamonga, California, United States
- Next Phase Research Alliance — Boca Raton, Florida, United States
- Advanced Pharma CR, LLC — Miami, Florida, United States
- Hope Clinical Trials — Miami, Florida, United States
- Kendall South Medical Center, Inc. — Miami, Florida, United States
- Quad Clinical Research — Chicago, Illinois, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Inquest Research — Baytown, Texas, United States
- Olympus Family Medicine — Salt Lake City, Utah, United States
- South Ogden Family Medicine Center — South Ogden, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.